explore -WSS

explore

author：entertainment 2025-09-27 13:04:22 - browse：5

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： UCLA team creates talking throat patch for voice disorders

explore

WSS

Pushing for an NIH office for post

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

Medicare coverage of Wegovy, once blocked, now looks possible

Shkreli is convicted of fraud. Can pharma finally slam the door on him?

WuXi out of biotech trade group, U.S. and China relations to blame

President Biden's budget: Here's what you might have missed

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Bristol, Sangamo, Gilead, and more

23andMe had bad news about my health. I wish a person had delivered it

Why scientists need input from humanists on sensitive research

Walensky prepares to leave CDC — and Congress — behind

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Malaria cases in Florida and Texas: Here’s what you need to know

The best solution to the drug shortages problem

Duchenne breakthrough therapy leaves behind pioneering families

American woman, child freed after being kidnapped in Haiti last month

knowledge

Boston's new lab space is opening empty

What to know about Virgin Galactic's 1st mission taking paying customers to space

For Cytokinetics, FDA rejection of heart drug would help, not hinder

Readout Newsletter: Bristol, Sangamo, Gilead, and more

FDA advisers back CAR

Readout Newsletter: CAR

Wikipedia

focus

explore

explore